Dogwood Therapeutics, Inc. Price & Performance (DWTX)

Dogwood Therapeutics has emerged from the merger of Virios Therapeutics and Wex Pharmaceuticals, now focusing on three key programs: Halneuron for chemotherapy-induced neuropathic pain, IMC-1 for fibromyalgia, and IMC-2 for Long-COVID. The company secured $23 million in new funding, positioning it to accelerate clinical development through late 2025.123

Virios Therapeutics stock climbed 14.5% on Friday with trading volume nearly doubling its average. The company's market capitalization now stands at $82 million. The jump follows increased attention to its antiviral therapies for fibromyalgia and Long-COVID, reflecting renewed investor interest in its clinical pipeline.45

A recent $23 million capital infusion, following Dogwood Therapeutics’ formation through a business combination, is set to fund late-stage trials for Halneuron and IMC-2. The company also enacted a 25-for-1 reverse stock split to maintain Nasdaq listing compliance, further supporting its growth and development plans.36